Drugs / FSH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07862725 | Oct 2026 → Oct 2027 expected | oligoasthenoteratozoospermia | Hamad Medical Corporation | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FSH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07862725 ↗ |
| Route | Subcutaneous | “Participants will receive the same antioxidant regimen plus FSH 150 IU administered subcutaneously three times weekly for 6 months.” NCT07862725 ↗ |